IOVANCE BIOTHERAPEUTICS, INC. quarterly report, Q1 FY2014

Business context and reporting period

Lion Biotechnologies, Inc. (formerly Genesis Biopharma, Inc.; later known as Iovance Biotherapeutics) filed this unaudited Form 10-Q for the quarter ended March 31, 2014. The company was a development-stage biotechnology business developing autologous tumor-infiltrating lymphocyte (TIL) cell therapies, initially focused on metastatic melanoma. It had no commercial products or revenue.

Financial performance and liquidity

Operating cash outflow was partly offset by $542,500 of warrant-exercise proceeds; cash declined $1.73 million during the quarter. The company reported a 14-to-1 current ratio and no long-term debt. It paid $941,659 in past-due NIH license amounts in January. No revenue or gross margin was reported, so a meaningful margin comparison is not available.

Material changes versus the prior comparable period

• Net loss increased to $2.26 million from $1.05 million, primarily as operating activity and expenses expanded; Q1 2013 included $341,616 of interest expense on debt later converted or cancelled in the May 2013 restructuring, while Q1 2014 had none.
• Operating expenses rose to $1.96 million from $435,000. Non-cash share-based compensation included in operating expenses increased to $1.07 million from $87,386.
• Research and development expense was $303,000 versus $270,000, including the $250,000 quarterly NCI CRADA payment in each period.
• Cash decreased from $19.67 million at year-end to $17.94 million at quarter-end. The company received a further $860,855 from warrant exercises in April, bringing reported post-quarter warrant proceeds to approximately $1.40 million.

Outlook, commentary, and risks

• Management expected operating expenses to rise as it expanded research and development, staffing, and plans for a Tampa research facility. It did not expect product or licensing revenue in 2014.
• Management said March 31 cash should fund its planned operations for at least 12 months, but stated that substantially more funding would be needed to complete development and obtain regulatory approvals. Potential sources include securities offerings and strategic alliances.
• The filing gives inconsistent 2014 spending estimates: the liquidity note says approximately $8–10 million, while MD&A says approximately $10–12 million. Management cautions that the budget may change materially.
• Contractual commitments include $1 million annually under the NCI CRADA, in quarterly installments through August 2016, and contingent NIH royalties and milestone payments. NIH milestone payments could total $6.05 million for melanoma or $36.3 million across the four licensed indications if all milestones are achieved. Discussions about additional NIH technology could increase future costs; potential surrender of certain patents could reduce obligations.
• On April 23, 2014, the company received an SEC subpoena in an investigation concerning unaffiliated Galena Biopharma. The subpoena did not state whether Lion itself was under investigation; Lion said it was cooperating. The filing reported no other pending legal proceedings.
• Potential dilution was substantial: at March 31, options covered 638,750 shares, warrants 12,156,156 shares, and preferred stock was convertible into 6.65 million common shares. The filing reported 22,437,300 common shares outstanding at May 15.

Important facts for investors to verify

1. Reconcile the conflicting $8–10 million and $10–12 million 2014 expenditure estimates and assess the cash runway against actual spending.
2. Track clinical-development progress, regulatory requirements, and the timing and cost of any additional NIH licenses or planned trials.
3. Monitor financing needs, warrant exercises, preferred-stock conversion, and other potential dilution.
4. Follow developments concerning the SEC subpoena and any resulting disclosure or financial impact.
5. Confirm contingent NIH milestone and royalty obligations, including any changes arising from patent surrender or amended licensing terms.